secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tenaya Therapeutics, Inc. (TNYA)
CIK:        0001858848
Form:       8-K
Filed at:   2022-03-23T23:59:59+00:00
Accession:  0000950170-22-004414
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenaya reports FY2021 net loss $72.7M; cash runway into H2 2023; three programs advancing
--------------------------------------------------------------------------------

- Cash, equivalents and investments $251.3M at Dec 31, 2021 vs $128.5M year-end 2020; runway to H2 2023.
- R&D expenses $54.4M in FY2021 (up from $31.1M); G&A $18.4M (up from $7.8M).
- Net loss $72.7M ($4.10/share) vs $38.4M ($39.50/share) in 2020.
- TN-201 IND submission for MYBPC3 HCM expected H2 2022; TN-301 IND H2 2022; TN-401 IND in 2023.
- Appointed Sunita Sethi (SVP Regulatory) and Naymisha Patel (SVP Quality); cGMP facility in Union City to be operational H1 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858848/000095017022004414/0000950170-22-004414-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858848/000095017022004414/tnya-20220323.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-004414

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer